Research programme: diabetes therapy - RheoscienceAlternative Names: RHS-15; RHS-16
Latest Information Update: 28 Jun 2011
At a glance
- Originator Rheoscience
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 06 Aug 2007 Preclinical trials in Diabetes mellitus in Denmark (unspecified route)